Editas Medicine announces U.S. court of appeals for the federal circuit affirms favorable U.S. patent and trademark office decision in CRISPR interference
Monday, September 10, 2018 Editas Medicine, Inc., a leading genome editing company, announced that the U.S. Court of Appeals for
Read More